

News Release

Corona del Mar, CA --- May 5, 2014



ImmunogenX™

ImmunogenX signs agreement with Flamentera to acquire rights to CypCel diagnostic for celiac disease management

Only effective non-intrusive diagnostic for celiac disease recovery

ImmunogenX™ is pleased to announce the signing of a definitive agreement with Flamentera AG, a Basel Switzerland pharmaceutical company, to acquire the assets of the company including the acclaimed CypCel™ diagnostic technology that forms the cornerstone of ImmunogenX commercialization strategy. CypCel is a patented investigational technology conceived and demonstrated by Prof. Chaitan Khosla at Stanford University. Flamentera acquired the rights to the technology from Stanford and funded a highly successful proof-of-concept clinical study (Moron et. al., Am J Gastroenterol 2013; 108: 1-8). Flamentera is now teaming with ImmunogenX to conduct a confirmatory trial to expand the population base and to make key improvements in the diagnostic methods. A key component is the mass spectrometric measure of a statin drug indicator of celiac intestinal health, a technology in which ImmunogenX excels and possesses key intellectual property.

Dr. Jack A. Syage, CEO of ImmunogenX remarks “It is a pleasure to work with Flamentera and their executive team as we are completely aligned in our commercial and technical goals. ImmunogenX and Flamentera recognize that our best prospects to commercializing CypCel is through mutual collaboration.”

Dr. Olivier Valdenaire, Co-founder of Flamentera states “We are very proud of the progress we have made to date in demonstrating the efficacy of the CypCel diagnostic in an important clinical study. We are very fortunate to be partnering with ImmunogenX who we feel has the optimal combination of technical expertise, seasoned executive team, and financial resources to bring CypCel to the clinical market.”

As part of the acquisition agreement, Dr. Syage will join the Board of Directors of Flamentera.

About ImmunogenX

“ImmunogenX” (a subsidiary of Immunogenics LLC) was founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors. ImmunogenX is developing new advanced diagnostic screening methods to help individuals with suspected gluten sensitivities and/or diagnosed with celiac disease. For disease management we are extending and commercializing a successful clinical study for a metabolic marker compound that can measure the state of recovery of a celiac patient undergoing dietary intervention. This is a unique capability for which there are no other effective diagnostics and may also be useful for monitoring a variety of non-dietary therapies currently under investigation. For food safety we are pioneering advanced methods to identify new physiologically relevant gluten peptide sequences in wheat, barley, and rye grain to greatly improve on the capability to screen for the full range of gluten proteins in food products.

www.Immunogenx.com

For further information please contact

Jack A. Syage, PhD
CEO
714 357-0631
jsyage@immunogenx.com

“ImmunogenX™”, “Immunogenics™”, “CypCel™”, and “Allergenomics™” are trademarks of Immunogenics LLC